MétaCan
Menu
Back to cohort
Record W2963939436 · doi:10.1177/2050640619864848

A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®<sup>MMX®</sup>) for active, mild‐to‐moderate ulcerative colitis

2019· article· en· W2963939436 on OpenAlexaboutno aff
Silvio Danese, Ailsa Hart, Axel Dignaß, Gionata Fiorino, Édouard Louis, Stefanos Bonovas, Geert D’Haens, Iris Dotan, Gerhard Rogler, Kristine Paridaens, Laurent Peyrin‐Biroulet

Bibliographic record

VenueUnited European Gastroenterology Journal · 2019
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsnot available
FundersFerring
KeywordsMMXMedicineUlcerative colitisBudesonideInternal medicineTolerabilityClinical endpointAdverse effectProspective cohort studyGastroenterologyClinical trialCorticosteroidDisease

Abstract

fetched live from OpenAlex

Background Cortiment® MMX® (budesonide MMX®) is currently approved for the induction of remission in mild‐to‐moderate ulcerative colitis (UC) patients when 5‐ASA treatment is not sufficient. Data in real‐life settings are lacking. Methods This was a multicentre observational prospective cohort study conducted in Europe and Canada. Effectiveness, safety, and tolerability of Cortiment® MMX® in a real‐life setting of patients treated for mild‐to‐moderate UC was investigated. Patients were prescribed Cortiment® MMX® in accordance with the Summary of the Product Characteristics (SmPC). The primary endpoint was the clinical benefit of Cortiment® MMX® in routine practice (improvement ≥ 3 points in the clinical sub‐scores of the Ulcerative Colitis Disease Activity Index, UCDAI). Results Data from 326 patients with mild‐to‐moderate UC were analysed for the primary endpoint. Clinical benefit was achieved in 60.1% (196/326) of patients at the end of Cortiment® MMX® treatment. Clinical remission (UCDAI clinical sub‐score ≤ 1), full symptoms resolution (rectal bleeding (RB) = 0 and stool frequency (SF) = 0) and symptoms resolution (RB = 0 + SF ≤ 1) at the end of the Cortiment® MMX® treatment were achieved in 51.8%, 45.1% and 63.2% of patients, respectively. The median time to symptoms resolution was 30 days (range 29.0–36.0 days). Fifty patients (14.3%) had to discontinue Cortiment® MMX® due to adverse events; 17.5% of patients ( n = 61) reported at least one adverse event related to the study drug. Conclusions This was the first time that a large cohort study was conducted with Cortiment® MMX® in a real‐life setting. It demonstrated that Cortiment® MMX® is effective, safe and well tolerated in about 60% of UC patients.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.030
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.007
GPT teacher head0.257
Teacher spread0.249 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations15
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueUnited European Gastroenterology JournalSame topicInflammatory Bowel DiseaseFrench-language works237,207